Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel vs Docetaxel in Neoadjuvant Breast Cancer
NCT04182568Phase 4Unknown
- Sponsor
- Xijing Hospital
- Start
- Aug 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of paclitaxel in breast cancer (2 arms), sponsored by Xijing Hospital. Primary endpoint: Residual Cancer Burden at 2 years. Status: unknown.
02
Drugs
paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04182568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04182568.